誉衡药业(002437) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥593,133,301.68, a decrease of 12.92% compared to ¥681,168,970.96 in the same period last year[3]. - Net profit attributable to shareholders increased by 160.65% to ¥52,282,909.59 from ¥20,058,598.74 year-on-year[3]. - Basic and diluted earnings per share increased by 158.24% to ¥0.0235 from ¥0.0091 in the same period last year[3]. - The total operating revenue for the current period is ¥593,133,301.68, a decrease of approximately 12.92% compared to ¥681,168,970.96 in the previous period[20]. - The net profit for the current period is CNY 55,761,035.49, a significant increase from CNY 21,870,444.70 in the previous period, representing a growth of approximately 154%[21]. - The total comprehensive income attributable to the parent company is CNY 52,354,237.76, compared to CNY 19,344,563.25 in the previous period, representing an increase of approximately 171%[21]. - The operating profit for the current period is CNY 68,449,052.90, up from CNY 32,216,202.85 in the previous period, reflecting an increase of approximately 113%[21]. Cash Flow and Investments - The net cash flow from operating activities rose by 90.25% to ¥159,239,649.03, compared to ¥83,699,367.15 in the previous year[9]. - The net cash flow from investing activities was negative at -¥4,756,664.99, a decline of 118.92% compared to ¥25,147,232.08 in the previous year[9]. - The company experienced a net cash outflow from investing activities of CNY 4,756,664.99, contrasting with a net inflow of CNY 25,147,232.08 in the previous period[22]. - The net cash outflow from financing activities was CNY 164,988,138.09, compared to a net outflow of CNY 101,258,939.96 in the previous period, indicating a worsening cash flow situation[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,079,864,778.97, a decrease of 2.30% from ¥3,152,450,105.19 at the end of the previous year[3]. - Current liabilities decreased significantly to ¥1,168,200,638.82 from ¥1,412,228,273.02, a reduction of about 17.24%[18]. - The company's cash and cash equivalents at the end of the period are ¥700,893,734.65, down from ¥711,275,270.60, a decrease of approximately 1.06%[17]. - The cash and cash equivalents at the end of the period decreased to CNY 700,607,124.37 from CNY 1,237,435,456.33, a decline of about 43.4%[23]. Shareholder Equity and Stock - Shareholders' equity attributable to the parent company increased by 8.83% to ¥1,808,476,235.24 from ¥1,661,773,347.48 at the end of the previous year[3]. - The company's total number of ordinary shareholders at the end of the reporting period was 99,096[11]. - As of March 2024, the company's total share capital increased from 2,198,122,950 shares to 2,270,513,950 shares due to the completion of the 2024 restricted stock incentive plan[12]. - The company granted 72.391 million shares of restricted stock to 105 incentive targets, accounting for 3.29% of the total share capital at the time of the announcement[15]. - As of March 2024, the total shares held by Shen Zhenyu and her concerted actions amounted to 208.2724 million shares, representing a holding ratio of 9.17%[13]. Government Subsidies and Financial Expenses - The company received government subsidies amounting to ¥38,864,209.88, a significant increase of 355.03% compared to ¥8,540,930.78 in the previous year[8]. - Financial expenses decreased by 91.44% to ¥1,324,953.12 from ¥15,480,627.57 due to repayment of bank loans[8]. - The company received government subsidies amounting to RMB 28.1269 million, impacting the net profit attributable to shareholders by RMB 22.7125 million[14]. - The company reported a decrease in financial expenses to ¥1,324,953.12 from ¥15,480,627.57, a significant reduction of about 91.45%[20]. Research and Development - Research and development expenses for the current period are ¥14,704,935.33, compared to ¥13,997,253.96 in the previous period, representing an increase of approximately 5.06%[20]. Product Development and Market Competitiveness - The product Fluorobiphenyl Ester Injection won the bid for centralized procurement in 13 provinces in Guangdong and obtained incremental qualifications[14]. - The company signed a contract to acquire the marketing authorization for the drug Sitagliptin Metformin Sustained-Release Tablets, which received approval in February 2024[15]. - The shelf life of Potassium Chloride Sustained-Release Tablets was extended from 24 months to 36 months, enhancing market competitiveness[15]. - The company reported a fair value loss of RMB 11.4057 million from equity investments, an increase in loss of RMB 9.5803 million compared to the previous year[14].